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Introduction
Although transition metal complexes, such as cispla-
tin, carboplatin, and oxaliplatin, have been applied as 
anti-tumour agents over decades, there is a lack of data 
regarding the interaction of these metallo-drugs with the 
enzymes involved in phospholipid metabolism. These 
enzymes, such as phospholipase A, C, or D, are an impor-
tant part of intracellular signalling pathways, which con-
trol the cell growth and differentiation1,2.
Phospholipases A
2
 are esterolytic enzymes which 
hydrolyze membrane phospholipids producing free fatty 
acids (FFAs) and lysophospholipids (LPLs), thereby pro-
viding precursors for the biosynthesis of proinflamma-
tory lipid mediators. Pancreatic phospholipase A
2
 (PLA
2
) 
belongs to the type I PLA
2
 enzymes, which have been 
shown to elicit receptor-mediated cellular responses, 
such as the stimulation of prostaglandin production, the 
secretion of steroid hormones3,4, or cell proliferation5,6. 
This enzyme plays a critical role in cellular homeostasis 
due to the catalysis of a rate-limiting step in the forma-
tion of arachidonic acid and derived biomediators. 
Accordingly, it has been shown that pancreatic PLA
2
 
plays a role in  carcinogenesis, immune suppression, and 
the stimulation of cell proliferation, as well as invasion 
and metastasis7–9.
The main aim of this study has been to test whether 
cisplatin (routinely used in the therapy of solid tumours, 
such as ovarian cancers10,11) and dichloro(1,2-diamino-
cyclohexane)platinum(II) ([Pt(dach)Cl
2
]), which is one 
of metabolites of other routinely applied metallo-drug, 
oxaliplatin12,13, inhibit the activity of pancreatic PLA
2
. 
We have also studied potential interaction between the 
complexes and the enzyme. Porcine pancreatic PLA
2
 was 
used as the model system and the results obtained for the 
two enzyme assays demonstrate a clear inhibitory effect, 
indicating differences in the mode of interaction between 
the complexes and PLA
2
.
Materials and methods
Chemicals
[PtCl
2
(dach)], dichloro(1,2-diaminocyclohexane)  plati-
num(II), was synthesized as described in the 
literature14,15. The chemical analysis, UV-VIS, and nuclear 
magnetic resonance (1H-NMR) spectral data of this 
complex were in good agreement with those obtained in 
previous preparations. Cisplatin, [PtCl
2
(NH
3
)
2
], and 
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cis-diamminedichloroplatinum(II) were purchased from 
Sigma (Taufkirchen, Germany). Porcine pancreatic PLA
2
 
was purchased from Fluka (Neu-Ulm, Germany) show-
ing an activity of 163 U/mg protein; 1 U corresponds 
to the amount of the enzyme that hydrolyzes 1 µmol of 
3-sn-phosphatidylcholine in 1 min at 37°C and pH 8.0). 
The enzyme was used without further purification. In the 
experiments, we used lipids and lysolipids commercially 
available from Sigma (Taufkirchen, Germany) and Avanti 
Polar Lipids (Alabaster, MA, USA) as 10 mg/mL chloro-
form solutions and phosphatidylcholine (PC) extracted 
from hen’s egg yolk16. The detergent applied with the 
aim of increasing the surface area and decreasing the 
substrate’s surface concentration, deoxycholic acid, 
was purchased from Sigma (Taufkirchen, Germany). 
Matrices for matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS), 2,5-
dihydroxybenzoic acid (DHB), and sinapic acid (SA), 
as well as solvents (chloroform and methanol) and trif-
luoroacetic acid were purchased from Fluka and Sigma 
(Taufkirchen, Germany) and were used without further 
purification. Eggs for the isolation of lecithin were pur-
chased at the local supermarket.
Methods
Extraction of egg-yolk PC
The method for the isolation of PC from egg yolk was 
based on the total lipid extraction by the CHCl
3
:CH
3
OH, 
2:1 (v:v) mixture, the removal of water-soluble com-
pounds using a 1% NaCl solution and the precipitation of 
phospholipids in cold acetone. A detailed description of 
the procedure can be found elsewhere in literature16. The 
concentration of phospholipids was checked by modified 
Stewart’s colorimetric assay17 with the standard curve 
recorded with palmitoyl-oleoyl-phosphatidylcholine 
(PC 16:0, 18:1).
Preparation of samples for MALDI-TOF MS analysis
For the investigation of the kinetics of PLA
2
 by MALDI-
TOF MS, egg-yolk PC (1 mg/mL) was re-suspended in 
a Tris buffer (50 mM Tris, 100 mM NaCl, 5 mM CaCl
2
, 
5.4 mM deoxycholate, pH 8.5) and incubated with pan-
creatic PLA
2
 (0.1 mg/mL18). Separately, the enzyme was 
incubated with Pt(II) complexes (5 × 10−4 mg/mL) for 2.5 h 
and, afterwards, the suspension of phospholipids was 
added. The reaction was terminated after the indicated 
periods of time by the addition of chloroform/methanol 
(1/1, v/v) mixture, followed by vigorous vortexing. The 
chloroform layer was separated by centrifugation and 
taken for further analysis by MALDI-TOF MS.
The procedure of sample preparation demands the 
premixing of the sample and the matrix before applica-
tion on the sample plate, in order to ensure better repro-
ducibility. The sample was applied as 1.5 µL droplet on 
the sample plate and dried immediately under a warm 
stream of air.
The application procedure for the analysis of transi-
tion metal complexes by MALDI slightly differs from 
that described for lipids: in this case, the matrix/analyte 
mixture was left at room temperature to co-crystallize. 
This has been shown to yield the best results in terms of 
homogeneity and the reproducibility of the spectra19.
For the analysis of the binding properties of platinum 
complexes with PLA
2
 by MALDI-TOF MS, the enzyme 
(0.1 mg/mL) dissolved in a phosphate-buffered saline 
(PBS) buffer with 5 mM CaCl
2
 (pH 7.2) was incubated 
with the complexes (5 × 10−4 mg/mL) in the presence of 
PC (16:0, 18:1) (1 mg/mL) for 3.5 h. Both complexes and 
PC were prepared in the same buffer as the enzyme. 
Subsequently, a small volume of the sample (1 µL) and 
then the same volume of matrix solution were applied 
onto the MALDI target plate. This mixture was left at 
room temperature to co-crystallize.
MALDI-TOF MS
The MALDI-TOF mass spectra were acquired on a 
Voyager Biospectrometry DE Pro Workstation (PerSeptive 
Biosystems, Framingham, MA, USA) or Autoflex (Bruker 
Daltonics) MALDI-TOF mass spectrometers equipped 
with a pulsed nitrogen laser (337 nm). All spectra were 
acquired with delayed extraction conditions and under 
the reflector mode. For the lower m/z ranges, no low 
mass gate was set and all mass spectra of phospholipids 
and complexes were obtained using the reflector mode. 
The mass spectra were calibrated by setting the peak 
of the protonated DHB matrix to its appropriate value 
(155.034 Da). The MALDI-TOF MS analysis of the enzyme 
was conducted under delayed extraction conditions 
and in the linear mode. All spectra were acquired with 
a 10 mg/mL concentration of SA in an acetonitrile/water 
solution (volume ratios 1:1).
UV/Vis spectrophotometric titration
UV/Vis spectrophotometric titration was applied in order 
to detect the interaction between the complexes and the 
enzyme. Briefly, a series of solutions of PLA
2
 with Pt(II) 
complexes with varying concentrations of complexes 
was made in PBS (pH 7.4). The concentration of PLA
2
 was 
kept constant at 25 μM and different amounts of platinum 
complexes (in the concentration range from 2.5 to 250 
µM were added). The concentration ratios (cPLA
2
:cPt(II)) 
were in the range from 0.1 up to 10. After 1 h incubation at 
37°C, all spectra were recorded in the wavelength range 
240–400 nm. 
Colorimetric assay for enzyme activity
The colorimetric assay according to the description of the 
manufacturer (Sigma-Aldrich20) was applied for monitor-
ing the PLA
2
 activity. The precise description of the reac-
tion mechanism could not be found. We assume that the 
procedure was based on the measurement of the change 
in the concentration of Fe2+ ion (obtained by the reduction 
in the presence of hydroxylamine) bound to PC. As the 
concentration of PC decreases upon the action of PLA
2
, 
the measured absorbance value A
570
 also decreases. The 
scope of the plot of A
570
 in relation with time of incubation 
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represents the reaction rate and can lead to a conclusion 
about the effect of the complexes on the PLA
2
 activity.
results
In order to investigate the influence of the selected tran-
sition metal complexes on the activity of PLA
2
, two meth-
ods were applied: colorimetric assay and MALDI-TOF 
MS. In the first part of our study, the MALDI-TOF mass 
spectra of Pt(II) complexes and isolated phospholipids 
were analyzed, whereas in the second part, MALDI-TOF 
MS was applied for monitoring the activity of the enzyme 
and the assessment of the effect of the complexes on the 
production of lyso-phosphatidylcholine (LPC) in the 
PLA
2
-catalyzed reaction. These results were also con-
firmed by colorimetric assay.
MALDI-TOF MS of Pt(II) complexes
The signals arising from the Pt(II) complexes tested for 
their influence on the activity of PLA
2
 are rather complex 
because Pt consists of several natural isotopes; the one 
with the mass of 194.96 is the most abundant. The combi-
nation with other elements present in the complex makes 
its mass spectra even more complicated. Since a more 
detailed description and explanation of the MALDI-TOF 
mass spectra of transition metal complexes is given else-
where in literature21,22, we will make only a few remarks 
on that subject.
The spectrum of [Pt(dach)Cl
2
] (Figure 1A) consists of 
two groups of peaks, one of them is generated by the addi-
tion of sodium ion to the molecule m/z = 403.5, whereas 
the peak at m/z = 419.5 arises from the ion formed by the 
addition of potassium to the molecule. These peaks are 
described in detail in our previous study21,23. Other two 
peaks present in the spectra of [Pt(dach)Cl
2
] cannot be 
identified with certainty, but they are most probably gen-
erated by the addition of a matrix molecule.
In contrast to [Pt(dach)Cl
2
], the MALDI-TOF mass 
spectrum of cisplatin was rather difficult to acquire, 
because this Pt complex expresses rather high reactiv-
ity24. The positive ion MALDI-TOF mass spectra of cispla-
tin consist of three groups of peaks, one of which cannot 
be identified with certainty, i.e. the peak at m/z = 313.3 
could not be explained based on possible fragmentation 
reactions of this molecule. The presence of platinum in 
the ion group from which these peaks were generated 
can be assumed based on the characteristic peak pattern. 
Peaks around m/z = 323.4 and m/z = 339.4 are generated 
by the addition of one sodium ion or one potassium ion 
to the complex, respectively. It should be pointed out 
that the pattern of the group of peaks which arise from 
sodium adduct corresponds almost completely to the 
theoretical presentation of mass spectra obtained with 
the Selket program (data not shown).
MALDI-TOF MS of egg-yolk PC
PC—a substrate for PLA
2
—was isolated from egg yolk 
according to the previously described procedure. The 
organic extract was analyzed by MALDI-TOF MS and 
the corresponding positive ion mass spectrum is given 
in Figure 2A. The spectra were acquired with the DHB 
matrix and the signals obtained from it are indicated by 
asterisks. Other peaks are labelled according to their m/z 
ratio and their identity is also indicated in the spectrum 
trace.
The MALDI-TOF mass spectra have confirmed that the 
major species in the isolate is indeed PC; mostly PC con-
taining palmitic acid residue esterified on the sn-1 posi-
tion was identified. The following peaks are present:  (i) 
PC(16:0,18:1) (The fatty acid composition of phospholip-
ids is usually given in such a way that the first number 
represents the number of C-atoms and the second one 
the number of double bonds in the fatty acyl chain. The 
fatty acid on the sn-position of the glycerol backbone of 
the corresponding phospholipid is listed first.) The cor-
responding peaks are at m/z = 760.1, 761.4 and 783.3, 
Figure 1. The positive ion MALDI-TOF mass spectra of [Pt(dach)
Cl
2
] (a) and cisplatin (b). Inserts in both spectra are group of 
signals arising from the Pt complexes and are given to emphasize 
their complexity. The signals arising from the complexes are 
emphasized with rectangles in both spectra. MALDI-TOF mass 
spectra of Pt(II) complexes are acquired with 2,5-DHB as matrix, 
under delayed extraction conditions and in the reflector mode.
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molecular ion, the proton, and sodium adducts, respec-
tively and (ii) PC (18:0, 18:2). Peak at m/z = 809.3, the 
sodium adduct. Besides PC, there are also small amounts 
of phosphatidylethanolamine (PE), phosphatidylserine, 
and sphyngomyelin (SM) detectable in the spectra. In 
addition, certain amount of LPC could be detected, but 
its intensity significantly increased after the incubation 
with PLA
2
, as it will be shown later. The presence of other 
phospholipid species in the isolate does not disturb fur-
ther experiments, as pancreatic PLA
2
 uses preferentially 
PC as the substrate25. Therefore, the increase in the con-
tent of lyso-phospholipids will be used as the measure 
of the PLA
2
 activity, as it has already been shown in our 
previous work18,26.
Since it is demonstrated that Pt complexes might also 
have esterase activity27, we have performed control mea-
surements, i.e. the phospholipids were incubated with 
complexes only and the corresponding mass spectra 
were acquired and presented in Figure 2B. Only the mass 
region of phospholipids is presented in order to dem-
onstrate that the ratio between the intensity of signals 
arising from the sodium adduct of PC (signal of the sub-
strate, S
s
) and that arising from the sodium adduct of LPC 
(signal of the product, S
p
) does not change significantly in 
the presence of the complex. The left trace represents the 
MALDI-TOF mass spectrum of phospholipids incubated 
without complexes, the middle trace is acquired from 
phospholipids incubated with cisplatin, and the spec-
trum to the right represents the phospholipids incu-
bated with [Pt(dach)Cl
2
]. The group of peaks in the mass 
region, between m/z = 560 and 670 (not labelled in the 
spectra), most probably represents the PEs and SMs and/
or certain fragmentation products generated upon laser 
irradiation28.
PLA
2
-catalyzed production of LPC
Positive ion MALDI-TOF mass spectra of the reaction 
mixture obtained after the indicated periods of incuba-
tion of PC with PLA
2
 are given in Figure 3. The peaks are 
labelled according to their m/z ratios and the identity of 
relevant signals is given in the figure. It is obvious that 
the hydrolysis of PC catalyzed by PLA
2
 takes place very 
quickly after the addition of the enzyme: already after 
2 min incubation, the signals arising from PC are difficult 
to detect in the spectra. After 40 min, no signals arising 
from PC could be detected. Since this species is easily 
detectable in the MALDI-TOF mass spectra29 due to its 
preformed positive charge, it is possible to affirm that the 
entire amount of the substrate has been converted into 
LPC (16:0). The ratio between the sodium adducts of the 
reaction product (LPC) and the substrate (PC) was taken 
as the measure for monitoring the consumption of PC 
Figure 2. (A) The positive ion MALDI-TOF mass spectrum of egg-yolk lecithin, (B) the mass region of phosphatidylcholine without the 
Pt(II) complexes (left), with cisplatin (middle), and with [Pt(dach)Cl
2
] (right). The signals are indicated by their m/z ratio together with their 
identity. Peaks arising from the matrix 2,5-DHB are labelled with an asterisk. The lines indicating the intensity of the signal arising from PC 
(S
s
) and from the product LPC (S
p
) are given in the spectra. All MALDI-TOF mass spectra were acquired with DHB matrix, under delayed 
extraction conditions and in the reflector mode. 
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and the assessment of the influence of the complexes on 
the enzymatic activity of PLA
2
.
In Figure 4A, the ratio between the intensity of the LPC 
and PC peaks (S
p
/S
s
 ratio) calculated from the MALDI-
TOF mass spectra acquired after different incubation 
periods of egg-yolk PC with PLA
2
 with or without Pt(II) 
complexes is given as a function of the incubation time. 
This ratio can be used as the measure for the amount of 
LPC produced; it can also be used to estimate the influ-
ence of Pt(II) complexes on the activity of PLA
2
, as dem-
onstrated in our previous work. Obviously, compared to 
the results obtained in the presence of either cisplatin or 
[Pt(dach)Cl
2
], the greatest amount of LPC has been pro-
duced in the absence of the complexes. The amount of 
LPC under all tested conditions increases during the first 
200 s after the initiation of the reaction, to subsequently 
achieve the plateau level. Further incubation of egg-yolk 
PC with PLA
2
 does not result in significant increase in the 
amount of LPC.
The data obtained by colorimetric assay for the first 
3 min of the reaction (with or without Pt(II) complexes), 
which approximately represents the linear part of the 
S
p
/S
s
 values calculated from the MALDI-TOF mass spec-
tra (Figure 4A), are presented in Figure 4B. In a similar 
manner as in the MALDI-TOF mass spectra, the highest 
reaction rate is observed for the sample in which egg-yolk 
PC was incubated with PLA
2
 without Pt(II) complexes, 
whereas significant decrease is observed in the presence 
of both Pt(II) complexes tested in this study. Insignificant 
differences are observed in the influence of cisplatin 
compared to [Pt(dach)Cl
2
].
The degree of the enzyme inhibition in the presence 
of two complexes could be calculated from MALDI-TOF 
mass spectra (Figure 4A) from the first linear part of the 
graph, according to the equation:
i
v v
v
=
−0
0
 where ν
0
 is the rate of a reaction in the absence of inhibi-
tor (control reaction) and ν the rate of a reaction in the 
presence of inhibitor. The i value in the absence of com-
plexes is zero and the values obtained for the enzyme in 
Figure 3. MALDI-TOF mass spectra of egg-yolk PC incubated 
for indicated periods of times with PLA
2
. Signals of interest are 
indicated according to their m/z ratios and their identity is given 
in the spectra traces. All other experimental conditions are like for 
the spectra presented in Figure 2.
Figure 4. (A) The ratio between the LPC signal intensity and 
PC signal intensity (S
p
/S
s
) calculated from the MALDI-TOF 
mass spectra of egg-yolk lecithin incubated with PLA
2
, which is 
previously incubated with Pt(II) complexes in the relationship 
with the time of incubation. (B) Absorbance of the reaction mixture 
monitored for 3 min of incubation of egg-yolk PC (1 mg/mL) with 
0.1 mg/mL PLA
2
 with or without Pt(II) complexes (5 × 10−4 mg/mL) 
in dependence of the time of incubation. (C) Degree of inhibition 
of the PLA
2
 activity obtained in the presence of Pt(II) complexes. 
Each value in both graphs represents the mean value from at least 
three independent measurements.
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the presence of cisplatin and [Pt(dach)Cl
2
] were 0.86 and 
0.59, respectively (Figure 4C). Obviously, much stronger 
inhibition of the enzyme activity (86%) was determined 
in the presence of cisplatin, compared to other complex 
tested.
Binding of Pt(II) complexes to PLA
2
In the next stage of our experiments, we tried to detect 
binding of the tested complexes to the enzyme in order 
to explain the inhibitory effect of the complexes on the 
enzyme activity. For this purpose, PLA
2
 was incubated 
with the complexes for three and a half hours and the 
MALDI-TOF mass spectra of a protein were acquired. We 
expected a mass shift towards higher m/z values in the 
MALDI-TOF mass spectra of PLA
2
 after the incubation 
with both complexes. PLA
2
 yields two peaks at m/z = 13801 
and at a higher mass m/z = 13991 (Figure 5A). It is, how-
ever, usual that the fraction of PLA
2
 isolated from porcine 
pancreas contains isoform with a higher mass. This spec-
tra pattern does not change with the addition of PC (16:0, 
18:1), i.e. the enzyme substrate (trace 5B). In the spec-
tra of the enzyme incubated with cisplatin (Figure 5C), 
and cisplatin and phosphatidylcholine (Figure 5D), new 
signal appears at m/z = 14,220, which corresponds to the 
addition of [Pt(NH
3
)
2
]2+ to the higher mass isoform of the 
enzyme. The bond between the enzyme and [Pt(dach)
Cl
2
] could not be detected by MALDI-TOF MS (data not 
shown).
In addition to MALDI-TOF mass spectrometric detec-
tion of the interaction between the complexes and the 
enzyme, we have also tried to detect the interaction of 
complexes with PLA
2
 by spectrophotometric titration, 
i.e. recording the UV spectrum of the enzyme upon addi-
tion of increasing amounts of a complex, i.e. with differ-
ent R values (R value represents the ratio between the 
molar concentration of PLA
2
 and the added complex). 
The coordination of a platinum drug to a protein causes 
changes in the protein conformation. They are detected 
as a change in the aromatic chromophores in the UV 
spectra of the protein. The resulting UV spectra are given 
in Figure 6: in (A) the spectra recorded upon the addition 
of increasing concentrations of cisplatin, in (B) the spec-
tra recorded upon the addition of increasing concentra-
tions of [Pt(dach)Cl
2
]. The graph given in (C) shows the 
dependence of A
280
 from the R values.
In the case of cisplatin, the hyperchrome effect 
occurs with a decrease in the R value, i.e. an increase in 
the concentration of cisplatin (Figure 6A). This behav-
iour was also detected in the studies dealing with the 
interactions of cisplatin with serum proteins30. A differ-
ent situation has been observed in the case of [Pt(dach)
Cl
2
] (Figure 6B). In this case, the absorbance at 280 nm 
increases as the R values increase up to R = 1, i.e. the 
equal concentrations of the complex and the enzyme. 
For the R values >1, the effect could be described as 
hypochromic (Figure 6C).
Discussion
Interaction of Pt(II) complexes with pancreatic PLA
2
The interaction of potential metallo-drugs with enzymes 
is of great importance having in mind that enzymes are 
target molecules for the therapy of various diseases. In this 
study, we have demonstrated that cisplatin and [Pt(dach)
Cl
2
] inhibit the activity of pancreatic PLA
2
. Furthermore, 
the data obtained in our study imply different mode of 
the interaction between the selected Pt(II) complexes 
and the enzyme: [Pt(dach)Cl
2
] is less reactive than cispla-
tin and lower degree of inhibition of the enzyme activity 
in the presence of [Pt(dach)Cl
2
] was obtained from the 
data presented in this work. The differences in reactivity 
between these two platinum complexes can be explained 
by the differences in their structure. Compared to cispla-
tin, [Pt(dach)Cl
2
] is a more sterically crowded complex. 
Namely, the substitution reactions of square-planar 
complexes, such as cisplatin and [Pt(dach)Cl
2
], proceed 
through associative pathways (A) involving the transi-
tion state with the coordination number 5. Both of these 
complexes have two labile leaving chlorido ligands in 
the cis-configuration but there is a crucial difference in 
non-labile ligands. Cisplatin has two non-labile ammine 
Figure 5. MALDI-TOF mass spectra of PLA
2
 (A), PLA
2
 incubated 
with PC (16:0, 18:1) (B), PLA
2
 incubated with cisplatin (C), and 
PLA
2
 incubated with the substrate, PC (16:0, 18:1), and with 
cisplatin (D). Enzyme (0.1 mg/mL) was incubated with the 
complex (5 × 10−4 mg/mL) and with PC (16:0, 18:1) (1 mg/mL) as 
described above, for other experiments. The MALDI-TOF mass 
spectra were acquired with sinapic acid as matrix under delayed 
extraction conditions and in linear mode. Presented spectra are 
representative of four measurements and they are average of 100 
individual laser shots.
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ligands, while [Pt(dach)Cl
2
] has one bidentate (dach) 
ligand which is much bulkier. That might indicate that 
the transition state has higher energy, while the rate of 
substitution reactions in the [Pt(dach)Cl
2
] complex is 
reduced. However, a more precise analysis of the mecha-
nism will be presented in our future studies.
The interaction of both tested complexes with PLA
2
 
leads to the inhibition of the enzyme activity as it has 
been demonstrated. It has already been shown that some 
Pt(II) complexes exhibit esterase activity27. Accordingly, 
there is a possibility that the LPC detected in the spectra 
of PC incubated with the enzyme in the presence of Pt(II) 
complexes is not a result of the PLA
2
-catalyzed hydrolysis, 
but of the esterolytic activity of tested complexes. We have 
excluded this possibility by simple control experiment 
(Figure 2B); therefore, we can state that all LPC which 
appear in the spectra are the result of PLA
2
-catalyzed 
hydrolysis of PC, and that the effect of tested complexes 
is the effect on the enzyme and not on the substrate.
Additionally, it seems that the inhibition modes of 
secretory PLA
2
 of various transition metal complexes are 
different. We have recently observed that the Pt and Ru 
complexes with bipyridine exhibit the acompetitive type 
of inhibition, and their interaction with PLA
2
 could be 
detected only in the presence of a substrate31. This type of 
inhibitory action implies that the binding of the complex 
increases after the interaction of the enzyme with the 
substrate, i.e. PC. This interaction changes the enzyme 
conformation, making the interaction site on the enzyme 
more accessible for the complex. Pancreatic PLA
2
 as a 
secretory type of enzyme contains a number of cysteine 
residues, which are potential binding sites for the inter-
action with Pt(II) complexes24,32–36, but the exact site of 
the interaction with complexes has not been known. On 
the other hand, the binding of cisplatin to PLA
2
 could be 
detected even without the presence of substrate (Figure 
5C), whereas the interaction between the other complex 
tested in our study, [Pt(dach)Cl
2
], with this enzyme is dif-
ferent. The binding of [Pt(dach)Cl
2
] to the enzyme could 
not be detected by MALDI-TOF MS (data not shown), 
and it can be assumed that the potential transient bond 
is not sufficiently stable under laser irradiation to be 
detected by this method. This fact and the data obtained 
by spectrophotometric titration (Figure 6) indicate a dif-
ferent mode of interaction compared to that in case of 
cisplatin.
Methodological approach
Readers may express their doubts regarding the experi-
mental techniques used in this study because they are 
not routinely established neither for the characteriza-
tion of transition metal complexes nor for the monitor-
ing the enzyme activity of phospholipases. Therefore, 
one of our tasks was to test the applicability of MALDI-
TOF MS for these purposes. A few remarks on the 
methodology have to be made at this point. First of all, 
MALDI-TOF MS enables fast and sensitive analyses of 
transition metal complexes, though some clusters, as 
Figure 6. Spectrophotometric titration of the PLA
2
 with cisplatin (A) and [Pt(dach)Cl
2
] (B). In (C), the dependence of the A
280
 from the R 
value (the ratio between molar concentration of PLA
2
 and the added complex) is given.
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observed in Figure 1A, are detectable in the spectra 
acquired with organic matrices. This methodological 
drawback has already been studied37. Although the 
matrix that we have chosen, 2,5-DHB, may not be per-
fect for the MALDI-TOF mass spectrometric analysis of 
transition metal complexes, it enables easy identifica-
tion and analysis of phospholipids28,29, which will be 
used in further work as a substrate for PLA
2
. However, 
a group of peaks which arise from the transition metal 
complexes—in this case from Pt(II) complexes—can be 
easily distinguished from other peaks in the MALDI-
TOF mass spectra. It should be pointed out that the 
spectra of cisplatin were rather difficult to acquire, 
most probably due to the high reactivity of this plati-
num complex. The pattern of the signal corresponding 
to the sodium adduct of cisplatin matches the theoreti-
cal presentation (data not shown); the somewhat more 
intense first peak in the group (at m/z = 321.4) is the 
only difference. Since the theoretical presentation does 
not include the matrix molecule (which itself gives sev-
eral signals in the mass spectra), the higher intensity of 
this peak might be the result of the superposition with 
the matrix signals. The other group of peaks, most prob-
ably arising from potassium adduct of cisplatin, do not 
completely match with the theoretical representation, 
implying some overlapping signals.
In addition to the characterization of the transi-
tion metal complexes, MALDI-TOF MS is not routinely 
used as the method for the determination of enzymatic 
activity. It is, therefore, necessary to test its capacity for 
being applied in the assessment of the enzyme activ-
ity of pancreatic PLA
2
. The MALDI-TOF MS approach 
offers numerous advantages over other methods25, and 
it was selected because of its simplicity (the substrate 
is in its native state and no derivatization is required), 
reproducibility, and sensitivity. The high sensitivity of 
this approach indicates that even rather low concentra-
tions of lyso-phospholipids (those in the femto-molar 
range), which are the product of the PLA
2
 activity, can 
be detected38.
However, the S
p
/S
s
 values, which were calculated 
from the MALDI-TOF mass spectra, should be used 
with some caution for determination of certain enzyme 
kinetic parameters25, as we have done in our work (deter-
mination of the degree of inhibition). These values are 
calculated from the first linear part of the curves only to 
numerically illustrate the differences in the efficiency of 
inhibition (which is obvious).
To check results obtained with MALDI, we have 
also monitored the reaction colorimetrically. The time-
dependent decrease in the values of the absorbance 
represents the reaction rate. The results obtained by 
this method were in agreement with the MALDI data 
(Figure 4). Accordingly, MALDI-TOF MS can be used as a 
reliable method for monitoring the enzyme activity.
In the light of the aim of our study, it is important that 
the S
p
/S
s
 ratio (the LPC signal intensity over the PC signal 
intensity) calculated from the MALDI-TOF mass spectra 
does not change in the presence of the Pt(II) complex, 
which indicates that all LPC arises from the PLA
2
-catalyzed 
reaction, as discussed above. This ratio has previously 
been used as the measure for the amount of the LPC 
produced by the catalytic activity of PLA
2
25. Therefore, we 
have confirmed its applicability in this case, as well.
Potential physiological relevance
Results obtained in numerous studies imply that the 
aberrant expression of secretory type of PLA
2
 is common 
in tumours derived from many different tissues, but the 
significance of these findings in the tumour development 
and progression could not be well established39.
Work of Avoranta and co-workers9 shows that sPLA 
type IIA is more expressed in the peritumoral mucosa in 
patients with colorectal carcinoma than in tumour tissue. 
Moreover, majority of vital tumour cells fail to express this 
enzyme, whereas PLA
2
 was accumulated in apoptotic and 
necrotic tumour cells. According to the hypothesis of the 
same authors9, PLA
2
, which is overexpressed in apoptotic 
and necrotic cells, might assist the host in the clearance 
of apoptotic cells and its inhibition can slow down this 
process.
On the other hand, secretory PLA
2
 was found to be 
upregulated in several types of malignancies, such as 
breast cancer40, prostate cancer41, or gastric cancers42. 
The level of its expression increases with increasing 
tumour grade and it was demonstrated that enzyme can 
be a marker for metastasis of some cancer types43.
In general, the nature and concentration of lipid media-
tors produced by the catalytic activity of PLA
2
, or derived 
from them, can determine whether the signals for the 
tumour development will be proliferative, apoptotic, or 
survival39. Some authors suggest that lost asymmetry in the 
tumour cells membrane results in the increase in the activ-
ity of PLA
2
IIA44, and that products of its activity can stimu-
late important apoptotic pathways via the activation of 
sphingomyelinases and subsequent release of ceramide45. 
From all these reasons, secretory types of PLA
2
 were con-
sidered as potential target for anti-tumour therapy46.
At this stage, we cannot state that the inhibition of 
sPLA
2
 with metallo-drugs (Pt, Ru, or Au) will lead to 
inhibition of the tumour growth; we can only indicate 
that the degree of enzyme inhibition depends on the 
nature of the ligand. Platinum complexes are, however, 
highly reactive species and might react with a number 
of proteins, although nucleic acids were considered 
as their primary targets. Therefore, findings presented 
in this work might be expanded on other enzymes 
involved in regulation of tumour growth and differ-
entiation. More work should be conducted in order to 
connect any physicochemical properties of a drug with 
its physiological effect.
conclusion
In conclusion, cisplatin and [Pt(dach)Cl
2
] interact with 
hog pancreatic PLA
2
, also implying the interaction with 
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the human enzyme, and this interaction inhibits the PLA
2
 
activity. Having this in mind, the question arises whether 
this type enzyme (secretory PLA
2
s) could be used as a tar-
get for anti-tumour therapy with metallo-drugs. Namely, 
it has been demonstrated that in the invasive form of the 
cancer tissue, the concentration of secretory pancreatic 
PLA
2
 is increased9. Accordingly, it remains to investigate 
in detail the impact of the inhibition of the activity of 
PLA
2
 on the tumour progression. The results presented 
in this study suggest the existence of different modes of 
binding of the Pt complexes to the enzyme, which may be 
considered as an advantage that can be further exploited 
in the development of therapeutical agents.
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